Total: $185.48M


Company

Location

Date

Amt. (M)

Details


Affinium Pharmaceuticals Inc.

Austin, Texas

8/30

$15

Affinium raised $15M in a follow-on Series A financing; investors were SV Life Sciences, Genesis Capital Partners and Forward Ventures, as well as Ontario Emerging Technologies Fund

Autifony Therapeutics Ltd.

London

8/23

£10 ($16.4)

Autifony received $16.4M from venture capital investors, including Imperial Innovations plc and SV Life Sciences

CoLucid Pharmaceuticals Inc.

Durham, N.C.

8/31

$7.5

CoLucid raised $7.5M of a planned $9.5M convertible note financing from its existing investors; participating investors included Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures

Embera NeuroTherapeutics Inc.

Shreveport, La.

8/16

$4.5

Embera closed a $4.5M round in a continuation of its Series A financings; investors were Louisiana Ventures LP, Louisiana Fund I and Themelios Ventures, as well as private investors

Enobia Pharma Inc.

Montreal

8/11

$40

Enobia raised $40M in a Series D round with Banc of America Merrill Lynch acting as exclusive placement agent

Jennerex Inc.

San Francisco

8/12

$8.6

Jennerex completed a private placement of $8.6M

Mirna Therapeutics Inc.

Austin, Texas

8/24

$1.5

Mirna closed a $1 .5M quity round with participation from several existing shareholders

Mission Therapeutics Ltd.

London

8/25

£6 ($9.8)

Mission raised $9.8M in its first round from Sofinova Partners, Imperial Innovations, SR One and the Roche Venture Fund

OncoCyte Corp.

Alameda, Calif.

8/25

$10

OncoCyte received $4M in cash and $6M in BioTime Inc. common shares through the financing

Proteon Therapeutics Inc.

Waltham, Mass.

8/15

$15.2

Proteon raised $15.2M in the Series C round

Pulmatrix Inc.

Lexington, Mass.

8/16

$14

Pulmatrix pulled in another $14M in a Series B round from 2009; investors were Polaris Venture Partners, 5AM Ventures, Arch Venture Partners and Novartis Venture Fund

SironRX Therapeutics Inc.

Cleveland

8/17

$3.4

SironRX closed a $3.4M Series A invements led by North Coast Angel Fund; additional investors were the Cleveland Clinic, JumpStart Inc., Glengary LLC, Ohio Tech Angel Fund III, Early Stage Partners, X Gen Ltd. and Fletcher Spaght Investments

Spinifex Pharmaceuticals Pty. Ltd.

Victoria, Australia

8/24

A$6.25 ($6.58)

Spinifex closed a $6.58M expanded Series B round; investors were GBS Venture Partners, Brandon Capital, Uniseed and Uniquest

Thetis Pharmaceuticals LLC

Rocky Hill, Conn.

8/24

$1.5

Thetis received $1.5M in seed funding from Connecticut Innovations, Stonehenge Partners and angel investors

To-BBB Technologies BV

Leiden, the Netherlands

8/30

€1.8 ($2.6)

To-BBB closed a $2.6M second close of its Series B round, which was supported by a consortium of informal investors

Tube Pharmaceuticals GmbH

Vienna

8/9

€1 ($1.4)

Tube raised $1.4M in a seed funding round

Vantia Therapeutics Ltd.

London

8/23

£8 ($13.1)

Vantia raised $13.1M through funding from Novo Ventures and SV Life Sciences to form the new company KalVista Pharmaceuticals Ltd.

Yaupon Therapeutics Inc.

Radnor, Pa.

8/15

$14.4

Yaupon raised $14.4M in a Series D round; investors were Vivo Ventures, Palo Alto Investors, Burril & Co. and Aperture Venture Partners


Notes:

Currency conversions are based on exchange rates at the time of the deal.

** Denotes the date the item ran in BioWorld International.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

ND = Not disclosed.